Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›ChinaAMC›83069

83069

ChinaAMC Hang Seng Biotech ETF

Passive ETF Equity

Not rated

The 83069 Exchange Traded Fund (ETF) is provided by ChinaAMC. It is built to track an index: Hang Seng Biotech Index. The 83069 ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.

CN¥13.07

-CN¥0.32 (-2.39%) 2 days ago

1:30 AM 09/10/26 Closed

1D price range

CN¥13.07CN¥13.07

52W price range

CN¥10.32CN¥16.94

YTD Perf.

+6.70%

YTD Flows

Annualized volatility

Fund AuM

€270M

Share class AuM

€270M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

HK0000711199HK0000744208HK0000955887

TER

0.5%

Inception date

3/18/2021

Issuer

ChinaAMC

Benchmark

Hang Seng Biotech Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
03174 CSOP Hang Seng Biotech ETF	-4.67%
KURE KraneShares MSCI All China Health Care Index ETF	-4.16%
371470 Mirae Asset TIGER Biotech Solactive ETF	-1.95%
09820 Global X China Biotech ETF	-

API

PerformanceDec 31, 2025 - Sep 10, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 07/31/26

Healthcare

96.32%

Consumer Non-Cyclicals

3.55%

Unavailable

0.13%

Latest 83069 news

No content available for this fund

FAQ about 83069

83069 is a Passive ETF. This ETF provides exposure to Biotechnology Equities.

83069 tracks the Hang Seng Biotech Index - HKD, through a full replication replication method.

83069 carries a total expense ratio (TER) of 0.5%, indicating the annual cost for holding the fund.

83069 was introduced to the market on March 18, 2021. It trades on Hong Kong

ChinaAMC Hang Seng Biotech ETF, 83069, is provided by ChinaAMC. Learn more about ChinaAMC here.

83069 oversees €270M in assets as of September 10, 2026.

83069 follows a distributing dividend policy, meaning it pays out income to investors. As of September 10, 2026, its 12-month trailing yield was 0.33%.

As of July 31, 2026, 83069 has significant geographic allocations in China, Hong Kong and Switzerland.

As of July 31, 2026, 83069 focuses largely on Healthcare and Consumer Non-Cyclicals.

As of July 31, 2026, 83069 holds 30 positions in its portfolio, with 83.29% of assets concentrated in its top 15 holdings.

As of July 31, 2026, 83069 top three holdings include BeOne Medicines Ltd., WuXi Biologics (Cayman), Inc. and Innovent Biologics, Inc..

The base currency of 83069 is HKD.

Top 10 holdings

Data as of 07/31/26

BeOne Medicines Ltd.

10.80%

WuXi Biologics (Cayman), Inc.

10.36%

Innovent Biologics, Inc.

10.33%

WuXi AppTec Co., Ltd.

8.22%

CSPC Pharmaceutical Group Ltd.

7.30%

Akeso, Inc.

7.30%

Sino Biopharmaceutical Ltd.

5.47%

Hansoh Pharmaceutical Group Co., Ltd.

5.14%

3SBio, Inc.

3.58%

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

3.32%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

ChinaAMC Hang Seng Biotech ETF

FAQ about 83069

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US